{"count":3,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/86e802da-44c5-46a4-a1f3-a90fd233c35a/","filing_uuid":"86e802da-44c5-46a4-a1f3-a90fd233c35a","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/86e802da-44c5-46a4-a1f3-a90fd233c35a/print/","filing_document_content_type":"text/html","income":null,"expenses":"2580000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Katie Oppenheim","dt_posted":"2026-04-20T21:00:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1001 PENNSYLVANIA AVENUE NW","registrant_address_2":"SUITE 650N","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":56838,"url":"https://lda.gov/api/v1/registrants/56838/","house_registrant_id":35186,"name":"SANOFI US SERVICES INC.","description":"sanofi-aventis U.S. Inc. discovers, develops, and markets prescription pharmaceuticals","address_1":"1455 PENNSYLVANIA AVENUE NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATIE OPPENHEIM","contact_telephone":"+1 202-585-3000","dt_updated":"2026-07-30T19:07:40.607412-04:00"},"client":{"id":159929,"url":"https://lda.gov/api/v1/clients/159929/","client_id":12,"name":"SANOFI US SERVICES INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-12-11"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.","foreign_entity_issues":"Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"340B; Medicare Negotiation, and Most Favored Nation.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Supply Chain Issues; and Importation issues.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; Type 1 Diabetes Screening; and Vaccines - General Issues","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/9dc78a89-313d-4bc5-9e1a-5a822ac14cdb/","filing_uuid":"9dc78a89-313d-4bc5-9e1a-5a822ac14cdb","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/9dc78a89-313d-4bc5-9e1a-5a822ac14cdb/print/","filing_document_content_type":"text/html","income":null,"expenses":"920000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Katie Oppenheim","dt_posted":"2026-07-20T22:58:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1001 PENNSYLVANIA AVENUE NW","registrant_address_2":"SUITE 650N","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":56838,"url":"https://lda.gov/api/v1/registrants/56838/","house_registrant_id":35186,"name":"SANOFI US SERVICES INC.","description":"sanofi-aventis U.S. Inc. discovers, develops, and markets prescription pharmaceuticals","address_1":"1455 PENNSYLVANIA AVENUE NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATIE OPPENHEIM","contact_telephone":"+1 202-585-3000","dt_updated":"2026-07-30T19:07:40.607412-04:00"},"client":{"id":159929,"url":"https://lda.gov/api/v1/clients/159929/","client_id":12,"name":"SANOFI US SERVICES INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-12-11"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements in AG Appropriations Bill; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.","foreign_entity_issues":"Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"340B; Medicare Negotiation, and Most Favored Nation.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"COINS Act Implementation; HR 9102 BINSA Bill; Supply Chain Issues; and Importation issues.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; China issues; Type 1 Diabetes Screening; and Vaccines - General Issues","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/26b74431-4796-4eed-bc68-023456cd422d/","filing_uuid":"26b74431-4796-4eed-bc68-023456cd422d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/26b74431-4796-4eed-bc68-023456cd422d/print/","filing_document_content_type":"text/html","income":null,"expenses":"1250000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Katie Oppenheim","dt_posted":"2026-10-20T23:52:44-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1001 PENNSYLVANIA AVENUE NW","registrant_address_2":"SUITE 650N","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":56838,"url":"https://lda.gov/api/v1/registrants/56838/","house_registrant_id":35186,"name":"SANOFI US SERVICES INC.","description":"sanofi-aventis U.S. Inc. discovers, develops, and markets prescription pharmaceuticals","address_1":"1455 PENNSYLVANIA AVENUE NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATIE OPPENHEIM","contact_telephone":"+1 202-585-3000","dt_updated":"2026-07-30T19:07:40.607412-04:00"},"client":{"id":159929,"url":"https://lda.gov/api/v1/clients/159929/","client_id":12,"name":"SANOFI US SERVICES INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-12-11"},"lobbying_activities":[{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; Type 1 Diabetes Screening; and Vaccines - General Issues","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B; Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General issues; Drug Price Negotiations within Inflation Reduction Act; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 830 HELP Copays Act; HR2880 Protecting Patients Against PBM Abuse Act; HR 5376 Inflation Reduction Act; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.","foreign_entity_issues":"Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"340B; Medicare Negotiation, and Most Favored Nation.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"COINS Act Implementation; HR 9102 BINSA Bill; Importation issues; and Supply Chain Issues.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149745,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MICHAEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}